补阳还五汤治疗特发性肺纤维化研究进展
Research Progress of Buyang Huanwu Decoction in the Treatment of Pulmonary Fibrosis
DOI: 10.12677/ACM.2023.132271, PDF,   
作者: 全立欣:黑龙江中医药大学,黑龙江 哈尔滨
关键词: IPF益气活血通络补阳还五汤综述IPF Yiqi Huoxue Tongluo Method Buyang Huanwu Decoction Overview
摘要: IPF是一种原因不明的慢性、进行性、不可逆性间质性肺疾病,现代医学以糖皮质激素及免疫抑制剂治疗为主,但难以解决肺部纤维化的根本问题。补阳还五汤作为益气活血通络的代表方剂,因其在治疗IPF方面疗效突出而受到重视。本文通过梳理IPF中医病因病机及现代医学发病机制、补阳还五汤理论研究、补阳还五汤治疗IPF的临床疗效观察等,使补阳还五汤在IPF实际临床治疗中发挥更大的作用。
Abstract: IPF is a chronic, progressive and irreversible interstitial lung disease of unknown cause, and mod-ern medicine is mainly treated with glucocorticoids and immunosuppressants, but it is difficult to solve the fundamental problem of pulmonary fibrosis. As a representative prescription for Yiqi Hu-oxue Tongluo Method, Buyang Huanwu decoction has been valued for its outstanding efficacy in the treatment of IPF. In this paper, by combing the etiology and pathogenesis of IPF in traditional Chi-nese medicine and the pathogenesis of modern medicine, the theoretical research on the theory of Buyang Huanwu decoction, and the observation of the clinical efficacy of Buyang Huanwu decoction in the treatment of IPF, this paper makes the Buyang Huanwu decoction play a greater role in the actual clinical treatment of IPF.
文章引用:全立欣. 补阳还五汤治疗特发性肺纤维化研究进展[J]. 临床医学进展, 2023, 13(2): 1957-1961. https://doi.org/10.12677/ACM.2023.132271

参考文献

[1] Hadjicharalambous, M.R. and Lindsa, Y.M.A. (2020) I Diopathic Pulmonaryibrosis: Pathogenesis and the Emerging Role of Long Non-Coding RNAs. International Journal of Molecular Sciences, 21, 524. [Google Scholar] [CrossRef] [PubMed]
[2] Krafts, K.P. (2010) Tissue Repair: The Hidden Drama. Organogenesis, 6, 225-233. [Google Scholar] [CrossRef] [PubMed]
[3] 谭支奎, 田正鉴. 田正鉴教授运用补阳还五汤加减方治疗特发性肺纤维化疗效观察[J]. 四川中医, 2014, 32(10): 113-114.
[4] 孙凯, 张虹. 特发性肺纤维化中医研究进展[J]. 光明中医, 2017, 32(16): 2440-2442.
[5] 黄云鉴. 肺纤维化中医治疗数据挖掘及养肺活血方干预机制研究[D]: [博士学位论文]. 南京: 南京中医药大学, 2017.
[6] 张登本, 孙理军. 全注全译黄帝内经(上) [M]. 北京: 新世界出版社, 2010
[7] 沈金鳌. 杂病源流犀烛[M]. 田思胜, 整理. 北京: 人民卫生出版社, 2006: 386-389.
[8] 王竹星, 申海莉, 王翔艳. 金匮要略白话精解: 中华治病医典[M]. 天津: 天津科学技术出版社, 2010: 155.
[9] 李菊莲, 王宇, 邓海娟. 肺痹与肺间质纤维化关系探讨[J]. 甘肃科技, 2003(12): 113-114.
[10] 张雪婷, 郑心. 从络病学角度探讨中医对特发性肺纤维化认识[J]. 福建中医药, 2015, 46(4): 56-57.
[11] 杨淦, 张先元, 曹栀, 董滟. 特发性肺纤维化与肺痹、肺萎关系浅析[J]. 亚太传统医药, 2015, 11(2): 52-53.
[12] Wolters, P.J., Collard, H.R. and Jones, K.D. (2014) Pathogenesis of Idiopathic Pulmonary Fibrosis. Annual Review of Pathology: Mechanisms of Disease, 9, 157-179. [Google Scholar] [CrossRef] [PubMed]
[13] 王恺京, 陆英, 赵倩, 等. 特发性肺纤维化的发病机制和临床治疗[J]. 中国医药导报, 2015, 12(12): 32-35+39.
[14] Keogh, B.A. and Crystal, R.G. (1982) Alveolitis: The Key to the Interstitial Lung Disorders. Thorax, 37, 1-10. [Google Scholar] [CrossRef] [PubMed]
[15] 边萌, 冯青青, 罗潇, 杜毓锋. LncRNACDKN2B-AS1/CDKN2A和p53在小鼠特发性肺纤维化及肺癌组织中的表达及意义[J]. 中华老年病研究电子杂志, 2021, 8(2): 10-16.
[16] In-vernizzi, R. and Molyneaux, P.L. (2019) The Contribution of Infection and the Respiratory Microbiome in Acute Exac-erbations of Idiopathic Pulmonary Fibrosis. European Respiratory Review, 28, Article ID: 190045. [Google Scholar] [CrossRef] [PubMed]
[17] Lauryna, N., et al. (2020) Role of Antioxidants in the Treatment of Gastroesophageal Refluxdisease-Associated Idiopathic Pulmonary Fibrosis. Current Opinion in Pulmonary Medicine, 26, 363-371.
[18] Al-Azzawi, M., et al. (2019) The Effect of Cigarette Smoking on the Oxidant-Antioxidantimbalancein Patients with Chronic Obstructive Pulmonary Disease. The Egyptian Journal of Chest Diseases and Tuberculosis, 68, 462-470.
[19] 肖美凤, 刘金玲, 杨岩涛, 等. 补阳还五汤的研究现状及其新药创制关键技术[J]. 中草药, 2018, 49(7): 1688- 1694.
[20] 颜晓霞, 袁帆, 郑访江. 补阳还五汤联合N-乙酰半胱氨酸胶囊治疗特发性肺纤维化患者的效果评价[J]. 内科, 2015, 10(4): 468-470.
[21] 宋占帅, 张娟, 张蓉, 等. 补阳还五汤联合汉防己田素片改善矽肺肺纤维化效果观察[J]. 山东医药, 2017, 57(42): 51-53.
[22] 陈宝华. 补阳还五汤治疗慢性阻塞性肺疾病合并肺间质纤维化的临床观察[D]: [硕士学位论文]. 成都: 成都中医药大学, 2013.